The downloadable single-page list recently released by the FDA has caused a stir in the industry. The FDA vape list states that “as of August 2023, 23 tobacco-flavored vapes and devices have been approved,” guiding legal sales for retailers. However, the document reveals ambiguities in regulatory language and disconnects from market realities. Analysis shows only 6 core devices are truly approved, with issues like category confusion and inconsistent standards. These contradictions highlight flaws in the FDA’s vape regulation approach.
I. The Dilemma of Regulatory Expressions Behind the List
(I) The “Word Game” of Statistical Calibers
The FDA identified 23 “vapes and devices,” but only 26% are unique devices, while 17 are refills or cartridges. For instance, Vuse Vibes and Vuse Ciros offer similar user experiences but are listed separately. Interestingly, the list includes Logic’s Vapeleaf, a heat-not-burn (HTP) product that heats solid tobacco capsules, differing entirely from traditional e-liquid vapes. This highlights inconsistencies in categorizing vaping products.
(II) The Controversy over the Classification of HTP Products
The FDA classifies Logic Vapeleaf as a “vape” while regulating Philip Morris International’s IQOS differently. Since 2019, IQOS has received eight PMTA authorizations, including three menthol-flavored refills, yet neither its device nor refills are listed. This raises industry concerns: why exclude IQOS, a heat tobacco product, from the vape category? Is the FDA avoiding endorsing low-risk menthol products due to its menthol ban focus?
II. The Market Presence of Truly Authorized Products
(I) The Core List After Excluding Interferences
After excluding HTP products and duplicate authorizations, there are only 6 FDA-authorized vapes actually on sale (7 if different nicotine concentration versions of NJOY Daily are subdivided):
- Logic series: Logic Pro (2 tobacco-flavored replacement cartridges), Logic Power (1 tobacco-flavored refill)
- NJOY series: NJOY Daily (2 nicotine concentrations/tobacco flavor), NJOY Ace (3 tobacco-flavored refills)
- Vuse series: Vuse Solo (2 tobacco-flavored refills), Vuse Vibe (1 tobacco-flavored refill)
These products all use artificial tobacco flavors and are concentrated under the ownership of a few tobacco giants, reflecting the tendency of the FDA’s authorization policy to favor traditional tobacco enterprises.
(II) The Market Paradox Under Regulatory Gaps
Since Brian King took over as the director of the CTP in 2022, the FDA has not approved any new e-liquid vapes but has continuously authorized IQOS refills. More notably, R.J. Reynolds has stopped selling the Vuse Ciro device, making the three previously approved Ciro Marketing Grant Orders (MGOs) by the FDA become mere paper documents. This phenomenon of “authorization means invalidation” highlights the doubtful practical application value of the FDA’s list.
(I) Consumer Demands Ignored by Regulation
Outside the FDA’s list, there is a huge unauthorized market:
Product types: Bottled e-liquids, refillable devices, fruit-flavored / menthol-flavored products, disposable vapes, etc. are all unauthorized.
Market distribution: vape stores, convenience stores, and globally popular brands (such as JUUL and SMOK) are all not on the list.
Nature of enterprises: Independent brands not under tobacco companies account for more than 60%.
Data shows that the FDA has issued Marketing Denial Orders (MDOs) to 323 enterprises, but there are still hundreds of PMTAs under review, creating a gray area of “pending regulation”.
(II) The Disconnection between Legal Risks and Actual Enforcement
The FDA’s stance that “unauthorized means illegal” faces challenges in judicial practice, as courts like the Fifth Circuit have blocked actions such as the Marketing Denial Order for Vuse menthol refills. This highlights the agency’s limitations when confronted with legal disputes. Meanwhile, thousands of products with unclear authorization continue to flood the market, creating compliance confusion for retailers. The FDA’s “non-proactive enforcement” strategy further weakens its role in guiding regulatory adherence.
IV. The Deep-seated Contradictions between Regulatory Logic and Market Demands
The FDA’s authorization list exposes three core issues:
Ambiguous technical definitions: Confusing the essential differences between vapes and HTP products, leading to chaotic classification standards.
Wavering policies: The contradictory attitude towards the menthol ban and the approval of low-risk products undermines regulatory credibility.
Fragmented consumer demands: Ignoring the needs of adult smokers for diversified products, and authorized products cannot meet the demand for harm reduction.
Industry experts point out that reasonable regulation should be based on scientific evaluation rather than political games. When the global vape market is growing at a rate of 20% per year, the FDA’s list policy is more like a “formal compliance” performance rather than a practical measure to truly promote public health goals. For consumers, recognizing the limitations of the authorization list and choosing compliant products that have passed third-party testing is the key to reducing risks.
